Caregen (CEO Yongji Jeong) participated in the Asian pharmaceutical and bio exhibition 'CPHI & PMEC China 2025' held in Shanghai, China from June 24th to 26th, and concluded the event by showcasing the company's peptide platform technology and major products.
CPHI China is an industry event with the participation of global pharmaceutical and bio companies and experts from over 120 countries. This year, it was held amidst a significant increase in demand for technical cooperation from local companies, driven by the Chinese government's policies to promote pharmaceutical industry innovation and health functional food industry advancement.
On the first day of the exhibition, Caregen presented its main peptide products, including 'ProGsterol' for blood sugar control and metabolic disease improvement, 'Korglutide' for oral GLP-1-based obesity treatment, and 'MyoKi' for muscle health improvement, through a solo seminar. These products are commercialized as health functional foods, but clinical design and mechanism of action research at the level of new drug development are systematically being conducted.
Industry experts evaluated that it was unusual for Caregen's functional food to have secured efficacy and safety through randomized, double-blind human application trials at the level of pharmaceutical clinical trials. Caregen's peptides were recognized for their technological competitiveness in that they have a low risk of side effects based on a precise targeting mechanism that selectively acts on specific cell receptors, and have high structural stability and bioavailability, which increases the possibility of expanding various indications.
During the exhibition, approximately 200 companies from 60 countries visited Caregen’s booth, and many Chinese and global pharmaceutical companies reviewed Caregen’s peptide product line as an early clinical stage platform and joint development partnership, and discussed the possibility of cooperation.
In particular, the wet macular degeneration treatment drug 'CG-P5' is currently in technology transfer negotiations with pharmaceutical companies in China, India, and South America. CG-P5 is a peptide eye drop candidate that overcomes the limitations of existing anti-VEGF injections, and its main technological difference is its delivery mechanism that passes through the vitreous body and reaches the retina through a non-invasive eye drop method. This technology is being evaluated as a case of overcoming an unresolved difficult problem in the ophthalmology field, and there is high demand for partnerships from global companies. In addition, 'CG-T1', a dry eye treatment drug, has received a proposal for technology transfer for animal medicine.
Oral GLP-1 peptide 'Coglutide' has technological advantages over injections in terms of ease of administration and reduced side effects, and is attracting attention as the first oral GLP-1 peptide to be commercialized. There is a lot of interest from Chinese pharmaceutical companies in partnerships, and technology transfer negotiations in the form of licensing out are underway in India, and other Asian countries are making proposals for supply contracts.
Global and Asian bio companies also discussed specific synergy strategies for treating obesity and muscle loss, such as proposing 'Myoki', an anti-myostatin peptide for complementing the side effects of muscle mass loss, as an integrated package with 'Coglutide'.
Caregen CEO Jeong Yong-ji said, “Through our participation in CPHI, we have been recognized for our potential as a global new drug development partner with scientific mechanisms of action and clinical reliability,” and added, “We will continue to create value in the global market through high-functional peptides that blur the boundaries between health functional foods and pharmaceuticals.”
- See more related articles
You must be logged in to post a comment.